InnoCon Medical ApS

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  3.0% 1.9% 1.2% 1.2% 1.2%  
Credit score (0-100)  59 70 80 81 81  
Credit rating  BBB A A A A  
Credit limit (kDKK)  0.0 3.4 419.8 488.8 1,023.8  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  -319 -487 4,496 4,331 5,226  
EBITDA  -319 -487 -420 -786 -579  
EBIT  -326 -508 -443 -807 -600  
Pre-tax profit (PTP)  -337.1 -528.8 -593.8 -953.3 -728.7  
Net earnings  -243.0 33.9 110.3 -178.1 -378.8  
Pre-tax profit without non-rec. items  -337 -529 -594 -953 -729  

 
See the entire income statement

Balance sheet (kDKK) 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  64.4 92.0 68.3 47.2 26.0  
Shareholders equity total  6,048 16,082 20,830 25,290 35,282  
Interest-bearing liabilities  5,200 0.0 94.7 399 688  
Balance sheet total (assets)  14,225 20,275 28,301 35,123 46,957  

Net Debt  2,278 -2,312 -3,081 -654 -1,737  
 
See the entire balance sheet

Volume 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  -319 -487 4,496 4,331 5,226  
Gross profit growth  4.4% -52.8% 0.0% -3.7% 20.7%  
Employees  6 7 8 8 9  
Employee growth %  50.0% 16.7% 14.3% 0.0% 12.5%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  14,225 20,275 28,301 35,123 46,957  
Balance sheet change%  7.4% 42.5% 39.6% 24.1% 33.7%  
Added value  -318.6 -486.8 -419.7 -783.1 -578.5  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  5,178 5,910 7,390 8,708 9,936  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  -3.0 -4.0 -5.0 -5.0 -5.0  

Profitability 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  102.2% 104.4% -9.9% -18.6% -11.5%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  -2.3% -2.9% -1.8% -2.5% -1.4%  
ROI %  -2.5% -3.0% -1.9% -2.7% -1.6%  
ROE %  -3.9% 0.3% 0.6% -0.8% -1.3%  

Solidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  42.5% 79.3% 73.6% 72.0% 75.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -715.2% 474.9% 734.1% 83.2% 300.3%  
Gearing %  86.0% 0.0% 0.5% 1.6% 1.9%  
Net interest  0 0 0 0 0  
Financing costs %  0.3% 1.1% 330.0% 61.9% 25.9%  

Liquidity 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.8 5.4 7.6 3.3 3.4  
Current Ratio  0.8 5.4 7.6 3.3 3.4  
Cash and cash equivalent  2,921.8 2,311.6 3,175.4 1,052.9 2,424.6  

Capital use efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -1,422.5 3,833.0 4,618.5 2,389.2 3,751.6  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
2019/12
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  -53 -70 -52 -98 -64  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  -53 -70 -52 -98 -64  
EBIT / employee  -54 -73 -55 -101 -67  
Net earnings / employee  -40 5 14 -22 -42